Circular RNAs are abundant, conserved, and associated with ALU repeats

WR Jeck, JA Sorrentino, K Wang, MK Slevin, CE Burd… - Rna, 2013 - rnajournal.cshlp.org
Circular RNAs composed of exonic sequence have been described in a small number of
genes. Thought to result from splicing errors, circular RNA species possess no known …

CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation

J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates… - Cancer discovery, 2018 - AACR
Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can
induce durable tumor regressions in some patients. To enhance the efficacy of existing …

[HTML][HTML] Monitoring tumorigenesis and senescence in vivo with a p16INK4a-luciferase model

CE Burd, JA Sorrentino, KS Clark, DB Darr… - Cell, 2013 - cell.com
Monitoring cancer and aging in vivo remains experimentally challenging. Here, we describe
a luciferase knockin mouse (p16 LUC), which faithfully reports expression of p16 INK4a, a …

Cells exhibiting strong p16INK4a promoter activation in vivo display features of senescence

JY Liu, GP Souroullas, BO Diekman… - Proceedings of the …, 2019 - National Acad Sciences
The activation of cellular senescence throughout the lifespan promotes tumor suppression,
whereas the persistence of senescent cells contributes to aspects of aging. This theory has …

Defining the toxicology of aging

JA Sorrentino, HK Sanoff, NE Sharpless - Trends in molecular medicine, 2014 - cell.com
Mammalian aging is complex and incompletely understood. Although significant effort has
been spent addressing the genetics or, more recently, the pharmacology of aging, the …

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

CM Goodwin, AM Waters, JE Klomp, S Javaid… - Cancer research, 2023 - AACR
Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key
genetic step that complements activation of KRAS in promoting the development and …

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

S He, PJ Roberts, JA Sorrentino, JE Bisi… - Science translational …, 2017 - science.org
Conventional cytotoxic chemotherapy is highly effective in certain cancers but causes dose-
limiting damage to normal proliferating cells, especially hematopoietic stem and progenitor …

Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression

JE Bisi, JA Sorrentino, PJ Roberts, FX Tavares… - Molecular cancer …, 2016 - AACR
Chemotherapy-induced myelosuppression continues to represent the major dose-limiting
toxicity of cytotoxic chemotherapy, which can be manifested as neutropenia, lymphopenia …

[HTML][HTML] CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell …

AY Lai, JA Sorrentino, KH Dragnev… - … for ImmunoTherapy of …, 2020 - ncbi.nlm.nih.gov
Background Combination treatment with chemotherapy and immune checkpoint inhibitors
(ICIs) has demonstrated meaningful clinical benefit to patients. However, chemotherapy …

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: a multicentre, randomised, double‐blind …

D Daniel, V Kuchava, I Bondarenko… - … journal of cancer, 2021 - Wiley Online Library
Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to
preserve haematopoietic stem and progenitor cells and immune system function from …